Skip to Main Content (Press Enter)

Logo UNICATT
  • ×
  • Home
  • Degrees
  • Courses
  • People
  • Outputs
  • Projects
  • Expertise & Skills

UNI-FIND
Logo UNICATT

|

UNI-FIND

unicatt.it
  • ×
  • Home
  • Degrees
  • Courses
  • People
  • Outputs
  • Projects
  • Expertise & Skills
  1. Outputs

Perioperative Outcomes of Robotic Radical Prostatectomy with Hugo™ RAS versus daVinci Surgical Platform: Propensity Score-Matched Comparative Analysis

Academic Article
Publication Date:
2024
Short description:
Gandi, C., Marino, F., Totaro, A., Scarciglia, E., Bellavia, F., Bientinesi, R., Gavi, F., Russo, P., Ragonese, M., Palermo, G., Racioppi, M., Lentini, N., Pastorino, R., Sacco, E., Perioperative Outcomes of Robotic Radical Prostatectomy with Hugo™ RAS versus daVinci Surgical Platform: Propensity Score-Matched Comparative Analysis, <>, 2024; 13 (11): N/A-N/A. [doi:10.3390/jcm13113157] [https://hdl.handle.net/10807/302183]
abstract:
Background/Objectives: There is an urgent need for comparative analyses of the intraoperative, oncological, and functional outcomes of different surgical robotic platforms. We aimed to compare the outcomes of RARP performed at a tertiary referral robotic centre with the novel HugoTM RAS system with those performed with a daVinci surgical system, which is considered the reference standard. Methods: We analysed the data of 400 patients undergoing RARP ± pelvic lymph node dissection between 2021 and 2023, using propensity score (PS) matching to correct for treatment selection bias. All procedures were performed by three surgeons with HugoTM RAS or daVinci. Results: The PS-matched cohort included 198 patients with 99 matched pairs, balanced for all covariates. Positive surgical margins (PSMs) were found in 22.2% and 25.3% (p = 0.616) of patients, respectively, in the HugoTM RAS and daVinci groups. No significant differences were found for other important perioperative outcomes, including median (1st–3rd q) operative time (170 (147.5–195.5) vs. 166 (154–202.5) min; p = 0.540), median (1st–3rd q) estimated blood loss (EBL) (100 (100–150) vs. 100 (100–150) ml; p = 0.834), Clavien–Dindo (CD) ≥ 2 complications (3% vs. 4%; p = 0.498), and social continence at 3 months (73.7% vs. 74.7%; p = 0.353). In multiple analyses, no associations were found between surgical outcomes (PSM, length of PSM, operative time, EBL, length of catheterization, length of hospital stay, social continence at three months after surgery, and CD ≥ 2 complications) and the robotic platform. Conclusions: Our findings demonstrate that HugoTM RAS enables surgeons to safely and effectively transfer the level of proficiency they reached during their previous experience with the daVinci systems.
Iris type:
Articolo in rivista, Nota a sentenza
Keywords:
HugoTM RAS system; comparative outcomes; daVinci surgical platform; prostate cancer; robot-assisted radical prostatectomy; robotic surgery
List of contributors:
Gandi, Carlo; Marino, Filippo; Totaro, Angelo; Scarciglia, Eros; Bellavia, Fabrizio; Bientinesi, Riccardo; Gavi, Filippo; Russo, Pierluigi; Ragonese, Mauro; Palermo, Giuseppe; Racioppi, Marco; Lentini, Nicolò; Pastorino, Roberta; Sacco, Emilio
Handle:
https://publicatt.unicatt.it/handle/10807/302183
Full Text:
https://publicatt.unicatt.it//retrieve/handle/10807/302183/612852/jcm-13-03157.pdf
Published in:
JOURNAL OF CLINICAL MEDICINE
Journal
  • Research Fields

Research Fields

Concepts (2)


LS7_2 - Medical technologies and tools (including genetic tools and biomarkers) for prevention, diagnosis, monitoring and treatment of diseases - (2024)

Settore MEDS-14/C - Urologia
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.4.5.0